Proteasome inhibitors function by blocking the enzymatic activity of the proteasome’s catalytic core. This prevents the breakdown of ubiquitin-tagged proteins, disrupting protein recycling within the cell.
As proteins accumulate, cellular stress pathways are activated. One major response is endoplasmic reticulum stress, which signals that the cell can no longer maintain protein balance. If unresolved, this stress triggers apoptosis.
Proteasome inhibition also affects transcription factors that regulate inflammation and survival signals. By suppressing these pathways, drugs further weaken diseased cells.
The specificity of proteasome inhibitors is carefully engineered to ensure sufficient disruption of abnormal cells while limiting harm to healthy tissues. This balance is critical for clinical success.
Understanding these molecular mechanisms has allowed scientists to refine drug design and improve therapeutic precision.